Abstract 1161: EZH2 inhibitor tazemetostat demonstrates activity in preclinical models of Bruton's tyrosine kinase inhibitor-resistant relapsed/refractory mantle cell lymphoma

2021 ◽  
Author(s):  
Jeffrey A. Keats ◽  
Arleide Lee ◽  
Jeremy C. Cunniff ◽  
Weiqing Chen ◽  
Revonda Mehovic ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Mantle Cell Lymphoma ◽  
Kinase Inhibitor ◽  
Cell Lymphoma ◽  
Bruton’S Tyrosine Kinase ◽  
Preclinical Models ◽  
Bruton's Tyrosine Kinase ◽  
Mantle Cell

scholarly journals Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059)

Leukemia ◽  
2019 ◽  
Vol 34 (5) ◽  
pp. 1458-1461 ◽  
Author(s):  
Simon A. Rule ◽  
Guillaume Cartron ◽  
Christopher Fegan ◽  
Franck Morschhauser ◽  
Lingling Han ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Mantle Cell Lymphoma ◽  
Kinase Inhibitor ◽  
Cell Lymphoma ◽  
Bruton's Tyrosine Kinase ◽  
Mantle Cell ◽  
Long Term Follow Up
Sign in / Sign up

Export Citation Format

Share Document